Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for DeliverySpyros A. Kalams, Ian Frank, Jonathan D. Fuchs et al.|The Journal of Infectious Diseases|2013Cited by 197
Phase 2 Study of an HIV-1 Canarypox Vaccine (vCP1452) Alone and in Combination With rgp120Nina D. Russell, Lawrence Corey, Barney S. Graham et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2006Cited by 104
Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteersPaul Goepfert, Thomas G. Evans, Georgia D. Tomaras et al.|Vaccine|2006Cited by 93
Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like ParticlesPaul Goepfert, Harriet L. Robinson, Marnie Elizaga et al.|The Journal of Infectious Diseases|2014Cited by 84
High‐Dose Recombinant Canarypox Vaccine Expressing HIV‐1 Protein, in Seronegative Human SubjectsPaul Goepfert, Helen Horton, M. Juliana McElrath et al.|The Journal of Infectious Diseases|2005Cited by 65